Tisdag 13 Januari | 04:19:55 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-24 08:30 Bokslutskommuniké 2026
2026-11-02 08:30 Kvartalsrapport 2026-Q3
2026-08-05 08:30 Kvartalsrapport 2026-Q2
2026-05-26 N/A Årsstämma
2026-05-18 08:30 Kvartalsrapport 2026-Q1
2026-02-27 08:30 Bokslutskommuniké 2025
2025-11-14 - Kvartalsrapport 2025-Q3
2025-08-01 - Kvartalsrapport 2025-Q2
2025-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-03-27 - Bokslutskommuniké 2024
2024-12-30 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Group bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Idag omfattar koncernen tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-02 13:03:00

By mutual agreement with the Board of Directors, Justin Pierce has stepped down from his position as Chief Executive Officer, with effect as of the date of this announcement. The decision has been taken for personal and health reasons, following the successful completion of the Company’s buy-and-build and strategic integration phase.

During his tenure, Justin Pierce led Magle Group through a period of significant transformation, including the execution of multiple acquisitions, the integration of operations, and the establishment of a consolidated platform to support future growth. The Board and Justin Pierce concur that the integration phase has now been successfully concluded and that this represents an appropriate juncture for a leadership transition as the Company enters its next phase of execution.

Stig Løkke Pedersen, Chairman of the Board, commented:
“Justin has led Magle Group through an extensive buy-and-build and integration period with strong commitment and professionalism. On behalf of the Board, I would like to thank him for his contributions and constructive collaboration, and we wish him every success in his future endeavours.”

Justin Pierce commented:
“Following an intensive period focused on building and integrating the Group, I have agreed with the Board that this is an appropriate time for a transition. I appreciate the Board’s support and the professional manner in which this process has been conducted. I would also like to thank my colleagues across the Group for their commitment and collaboration.”

With immediate effect, Aaron Wong, currently Chief Financial Officer of Magle Group, has been appointed Interim Chief Executive Officer. This appointment is intended to ensure continuity of leadership and day-to-day operations while the Board undertakes an evaluation of the Company’s longer-term leadership requirements.

Magle Group has experienced strong growth in recent years, accompanied by increased operational and organisational complexity. The Board believes that this leadership transition positions the Company well to advance into its next phase of development and execution. The Board remains confident in Magle Group’s strategy, financial position, and growth prospects, and confirms that the Company’s strategy, financial targets, and operational priorities remain unchanged.